Nuvalent has reported phase 1/2 lung cancer data, teeing the biotech up to talk to the FDA about an approval filing that could establish its neladalkib as a challenger to Pfizer’s Lorbrena.

Pfizer and Tris Pharma agreed to pay $41.5 million to settle allegations they altered testing methods to ensure their ADHD ...

WASHINGTON (AP) — U.S. regulators approved updated COVID-19 shots Wednesday but limited their use for many Americans — and removed one of the two vaccines available for young children. The new shots ...

NEW YORK/LONDON (Reuters) -The Pfizer and Novo Nordisk battle for obesity drug developer Metsera intensified on Thursday ...

The Food and Drug Administration on Wednesday authorized updated COVID-19 vaccines, but limited their use for most age groups and rescinded the emergency use authorization that made shots available ...

Pfizer and supplier Tris Pharma reached a $41.5 million settlement with Texas to resolve a lawsuit claiming they defrauded ...